Novel cytotoxic chemotherapies in small cell lung carcinoma

Diego Cortinovis, Paolo Bidoli, Stefania Canova, Francesca Colonese, Maria Gemelli, Maria Luisa Lavitrano, Giuseppe Luigi Banna, Stephen V. Liu, Alessandro Morabito

Research output: Contribution to journalReview articlepeer-review


Small cell lung cancer (SCLC) is one of the deadliest thoracic neoplasms, in part due to its fast doubling time and early metastatic spread. Historically, cytotoxic chemotherapy consisting of platinum–etoposide or anthracycline-based regimens has demonstrated a high response rate, but early chemoresistance leads to a poor prognosis in advanced SCLC. Only a fraction of patients with limited-disease can be cured by chemo-radiotherapy. Given the disappointing survival rates in advanced SCLC, new cytotoxic agents are eagerly awaited. Unfortunately, few novel chemotherapy drugs have been developed in the latest decades. This review describes the results and potential application in the clinical practice of novel chemotherapy agents for SCLC.

Original languageEnglish
Article number1152
Pages (from-to)1-17
Number of pages17
Issue number5
Publication statusPublished - Mar 1 2021


  • Chemotherapy
  • Immunotherapy
  • Lurbinectedin
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Novel cytotoxic chemotherapies in small cell lung carcinoma'. Together they form a unique fingerprint.

Cite this